FDA Database Clean-Up Causes Jump In "Concluded" Postmarketing Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
A more than two-fold increase in the number of concluded study requirements and commitments in fiscal 2009 appears largely attributable to a consulting firm's clean-up of FDA's postmarketing obligations database.
You may also be interested in...
FDAAA Post-Marketing Requirements Growing As Commitments Decline
Safety studies imposed under FDA Amendments Act authorities are a growing portion of sponsors’ post-approval study burden, while post-marketing commitments are declining, according to the latest FDA annual report on the status of post-marketing requirements and commitments.
FDAAA Post-Marketing Requirements Growing As Commitments Decline
Safety studies imposed under FDA Amendments Act authorities are a growing portion of sponsors’ post-approval study burden, while post-marketing commitments are declining, according to the latest FDA annual report on the status of post-marketing requirements and commitments.
Reauthorizations Cause Sponsor Angst For PREA, BPCA Studies, GAO Finds
The regular reauthorization of PREA and BPCA, when coupled with the long review horizon for pediatric studies at FDA, could be hindering sponsors’ willingness to conduct the trials, according to a Government Accountability Office Report.